REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|January 31, 2022
Daily OTC Pearl: Estroven
Author(s)Saro Arakelians, PharmD
Estroven can help reduce menopause symptoms such as hot flashes and night sweats, and helps to manage daily stress.
Advertisement
OTC/Lifestyle Pearl of the Day: Estroven
Indication: Estroven Complete Menopause Relief treats the symptoms of menopause.
Insight:
- Estroven Complete Menopause Relief is clinically shown to help decrease all menopause symptoms tested.
- Estroven reduces hot flashes and night sweats, supports restful sleep, boosts energy, helps to manage daily stress, mood, irritability, and menopause-related anxiety.
- Estroven contains naturally sourced rhapontic rhubarb, a botanical with a long history of use in Europe, which has been clinically shown to reduce menopause symptoms.
- Taken once daily.
- The 3 primary ingredients of Estroven include black cohosh, soy isoflavones, and rhapontic rhubarb extract.
Sources:
Advertisement
Related to this article
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5